Best Prostate Cancer Analysis Marseille Near Me

4worldlovers: Professor Frédéric Castinetti, of the DiPNET/MoPED team, is presiding the WorldMEN conference from 26 to 28 April at the...

Variations in the poly-histidine repeat motif of HOXA1 contribute to bicuspid aortic valve in mouse and zebrafish

In Nature Communications, the Genetic and Development of Cardiac Defects team described the role of HOXA1 in BAV.

Expanding the phenome and variome of the ROBO-SLIT pathway in Congenital Heart Defects

In collaboration with IGF (Inserm U1191) and three departments of pediatric and adult cardiology (Hôpital de la Timone...

Rare pigmented malformations and cancers are the subject of study for 25 associated partners and organizations in the...

Time-limited alterations in cortical activity of a knock-in mouse model of KCNQ2-related developmental and epileptic encephalopathy.

In collaboration with INMED (Inserm U1249), the Human Neurogenetics team shows transient cortical alterations in the...

Ultrasound-mediated blood-brain barrier opening improves whole brain gene delivery in mice.

Focused ultrasound (FUS) coupled with microbubbles appears as a technological breakthrough to deliver therapeutic agents...

Loss of MTX2 causes mandibuloacral dysplasia and links mitochondrial dysfunction to altered nuclear morphology

A knock-in mouse model for KCNQ2-related epileptic encephalopathy displays spontaneous generalized seizures and cognitive impairment

4worldlovers: Veracyte helps translate the complex tumor immune response into a clear path forward for our biopharma partners. We offer customized biomarker testing and analytical services to help them advance their therapeutic discovery, development and commercialization programs.

4worldlovers:
ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.


ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023